CERT2 is a Ceramide based Cardiovascular Risk Score which represents the next-generation in CVD risk assessment.
CERT2 enhances traditional lipid-based risk assessment reflecting both lipid and inflammatory related risk. CERT2 unravels hidden risk in healthy individuals as well as in CVD patients, and identifies residual risk in individuals on lipid-lowering therapy.
Order inquiry here
Utility
CERT2 is a Ceramide based Cardiovascular Risk Score
- Improves traditional lipid-based risk assessment and unravels hidden risk.
- Reflects both lipid and inflammatory related risk.
- Identifies a hidden risk in individuals not known to have coronary artery disease or elevated cholesterol levels.
- Identifies residual risk in CVD patients.
- Identifies residual risk in individuals believed to be on optimal lipid lowering therapy.
dScore is a ceramide-based type II diabetes risk score
- dScore addresses ceramide mediated insulin resistance and fat versus muscle composition to give more accurate risk of type II diabetes onset.
About
CERT2 Predicts the risk for cardiovascular disease events:
- Cardiovascular death
- Non-fatal and fatal myocardial infarction
- Stroke
- Heart failure
- MACE: Major adverse cardiovascular events
dScore estimates person’s probability to develop type II diabetes over the next ten years
Indications
The test can be used to assess the risk of cardiovascular events and diabetes in the following patient groups:
1) Cardiovascular Risk Assessment
- Adults with known cardiovascular risk factors or a family history of premature cardiovascular disease.
- Healthy adults, from age 40 for men and age 50 for women, as part of an overall cardiovascular risk assessment.
- Adults for whom statin or other cholesterol-lowering therapy is being considered based on the results of other risk assessments.
- Patients with coronary artery disease or individuals receiving lipid-lowering therapy, for the assessment of residual cardiovascular risk.
2) Type 2 Diabetes Risk Assessment
- Adults for the assessment of future risk of developing Type 2 diabetes.
CERT2 identifies risk for cardiovascular events in healthy population:
Ref: Hilvo et al. 2021. Eur Heart J. Open. 2021 doi:10.1093/ehjopen/oeab010
CERT2 identifies high-risk coronary heart disease patients:
Ref: Hilvo et al. 2020 Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur Heart J. 2020; 41:371-380.